J. Michael Graglia
J. Michael Graglia has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Kathryn Ann Helde
CURE SYNGAP1, San Diego, CA, USA
4 shared publications Virginie McNamar
CURE SYNGAP1, San Diego, CA, USA
2 shared publications- Aaron J. Harding
SynGAP Research Fund, San Diego, CA, USA
1 shared publication - Albert L. Misko
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
1 shared publication - Alexander K. Gonzalez
Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, PA
1 shared publication Alicia Harrison
Division of Neurology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
1 shared publication
Latest Publications
- Open Access
Characterization of Sleep, Spectral, and Epileptiform Activity in Individuals Aged 8–27 Years with SYNGAP1-Related Disorder Using an at-Home Dry EEG Headband
SYNGAP1-related disorder (SYNGAP1-RD) is associated with sleep disturbances, seizures, and neurophysiological abnormalities. However, in-lab EEG can be difficult to obtain due to the behavioral and sensory disorders associated with this condition. In this study we collected EEG in SYNGAP1-RD participants (n=30 enrolled, 27 contributing data) in a decentralized protocol using a dry electrode headband as a path to longitudinal, research-grade data collection in this population. At-home data collection was successful with 180 recordings containing over 1 hour of usable data collected from 23 participants. Across these recordings, sporadic interictal epileptiform discharges were present in 22 of 23 participants but electrographic seizures were not observed. Relative to an adolescent control population (n=10), SYNGAP1-RD participants showed increased wake after sleep onset, reduced sleep efficiency, and decreased time in N1 and N3 sleep stages along with increased time in N2. We reproduced prior findings from awake spectral EEG analyses, including elevated broadband power along with reduced relative alpha power and alpha-theta ratio in the SYNGAP1 cohort. Notably, differences in spectral power were tightly linked to sleep stage, revealing sleep-stage-dependent spectral biomarker dynamics not previously characterized in SYNGAP1-RD. Finally, we examined differences between variants producing truncations downstream of the GAP domain and those producing truncations before or within it, but analyses were limited by a small sample size (n=4 for the post-GAP variant). Overall, this study demonstrates the feasibility of at-home multi-night sleep EEG collection in participants with SYNGAP1-RD and led to both corroborative and novel findings.
Open AccessCharacterization of Sleep, Spectral, and Epileptiform Activity in Individuals Aged 8–27 Years with SYNGAP1-Related Disorder Using an at-Home Dry EEG Headband
SYNGAP1-related disorder (SYNGAP1-RD) is associated with sleep disturbances, seizures, and neurophysiological abnormalities. However, in-lab EEG can be difficult to obtain due to the behavioral and sensory disorders associated with this condition. In this study we collected EEG in SYNGAP1-RD participants (n=30 enrolled, 27 contributing data) in a decentralized protocol using a dry electrode headband as a path to longitudinal, research-grade data collection in this population. At-home data collection was successful with 180 recordings containing over 1 hour of usable data collected from 23 participants. Across these recordings, sporadic interictal epileptiform discharges were present in 22 of 23 participants but electrographic seizures were not observed. Relative to an adolescent control population (n=10), SYNGAP1-RD participants showed increased wake after sleep onset, reduced sleep efficiency, and decreased time in N1 and N3 sleep stages along with increased time in N2. We reproduced prior findings from awake spectral EEG analyses, including elevated broadband power along with reduced relative alpha power and alpha-theta ratio in the SYNGAP1 cohort. Notably, differences in spectral power were tightly linked to sleep stage, revealing sleep-stage-dependent spectral biomarker dynamics not previously characterized in SYNGAP1-RD. Finally, we examined differences between variants producing truncations downstream of the GAP domain and those producing truncations before or within it, but analyses were limited by a small sample size (n=4 for the post-GAP variant). Overall, this study demonstrates the feasibility of at-home multi-night sleep EEG collection in participants with SYNGAP1-RD and led to both corroborative and novel findings.
- Open Access
A prospective natural history study protocol for clinical trial readiness in synaptic disorders
Objective: STXBP1‐ related disorder ( STXBP1 ‐RD) and SYNGAP1 ‐related disorder ( SYNGAP1 ‐RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems. Both STXBP1 ‐RD and SYNGAP1 ‐RD are potential targets for disease‐modifying therapies, but there is limited information in the literature describing the natural history of either disorder, which impedes outcome selection for future clinical trials. The objective of this study is to develop a framework to better define and outline the clinical spectrum and longitudinal trajectories of STXBP1 ‐RD and SYNGAP1 ‐RD natural history, including development, behavior, seizure histories, and electrophysiology. Methods: Here, we describe a protocol, regulatory structure, and supportive preliminary data for multicenter, prospective natural history studies of STXBP1 ‐RD (STARR) and SYNGAP1 ‐RD (ProMMiS). The protocols incorporate gold standard clinician‐administered outcome measures including the Bayley Scales of Infant and Toddler Development 4th edition, Gross Motor Function Measure‐66, fine motor domains of the Peabody Developmental Motor Scales 3rd edition, parent‐reported outcome measures, epilepsy histories, and biomarker exploration. To date, the study has enrolled 164 individuals with STXBP1 ‐RD and 159 with SYNGAP1 ‐RD, with ongoing longitudinal assessments every 6 months in a subset of approximately 200 total individuals across both disorders. Results: Our data support that existing developmental measures are feasible, informative, and show minimal floor or ceiling effects. Furthermore, we demonstrate that medical record‐based seizure history reconstruction reveals unique epilepsy trajectories while minimizing burden to families. We observe disease‐specific patterns of developmental performance and distinct longitudinal seizure dynamics, highlighting the need for data generation in a gene/disorder‐specific manner for clinical trial readiness. Significance: In summary, we present a feasible natural history protocol with prospective data for two complex neurodevelopmental disorders with natural histories that have previously been incompletely characterized, within a regulatory framework that will support the use of these data to expedite clinical trial development.
Open AccessA prospective natural history study protocol for clinical trial readiness in synaptic disorders
Objective: STXBP1‐ related disorder ( STXBP1 ‐RD) and SYNGAP1 ‐related disorder ( SYNGAP1 ‐RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems. Both STXBP1 ‐RD and SYNGAP1 ‐RD are potential targets for disease‐modifying therapies, but there is limited information in the literature describing the natural history of either disorder, which impedes outcome selection for future clinical trials. The objective of this study is to develop a framework to better define and outline the clinical spectrum and longitudinal trajectories of STXBP1 ‐RD and SYNGAP1 ‐RD natural history, including development, behavior, seizure histories, and electrophysiology. Methods: Here, we describe a protocol, regulatory structure, and supportive preliminary data for multicenter, prospective natural history studies of STXBP1 ‐RD (STARR) and SYNGAP1 ‐RD (ProMMiS). The protocols incorporate gold standard clinician‐administered outcome measures including the Bayley Scales of Infant and Toddler Development 4th edition, Gross Motor Function Measure‐66, fine motor domains of the Peabody Developmental Motor Scales 3rd edition, parent‐reported outcome measures, epilepsy histories, and biomarker exploration. To date, the study has enrolled 164 individuals with STXBP1 ‐RD and 159 with SYNGAP1 ‐RD, with ongoing longitudinal assessments every 6 months in a subset of approximately 200 total individuals across both disorders. Results: Our data support that existing developmental measures are feasible, informative, and show minimal floor or ceiling effects. Furthermore, we demonstrate that medical record‐based seizure history reconstruction reveals unique epilepsy trajectories while minimizing burden to families. We observe disease‐specific patterns of developmental performance and distinct longitudinal seizure dynamics, highlighting the need for data generation in a gene/disorder‐specific manner for clinical trial readiness. Significance: In summary, we present a feasible natural history protocol with prospective data for two complex neurodevelopmental disorders with natural histories that have previously been incompletely characterized, within a regulatory framework that will support the use of these data to expedite clinical trial development.
- Open Access
- 12 January 2025
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 6
Roadmap to advance therapeutics for SYNGAP1-related disorder: a patient organization perspective from SynGAP Research Fund
SYNGAP1-related disorder (SRD) is a developmental and epileptic encephalopathy caused by a disruption of the SYNGAP1 gene. At the beginning of 2024, it is one of many rare monogenic brain disorders without disease-modifying treatments, but that is changing. This article chronicles the last 5 years, beginning when treatments for SRD were not publicly in development, to the start of 2024 when many SRD-specific treatments are advancing. We discuss the progress across many realms that have brought SRD to the forefront of drug development and highlight how Patient Advocacy Groups (PAGs) have had direct roles in accelerating the route to meaningful treatments for our children. We start with a summary of why SRD is an attractive pharmaceutical target. Second, we introduce the disease, the clinical features, and the number of patients. Next, we describe our PAG, our international partners and cite examples of the broad range of activities we believe are accelerating our pace toward treatments. We summarize the current SYNGAP1 pipeline and the status of each public project. Finally, we discuss two open questions that urgently need to be addressed in advance of clinical trials for SRD.
- 12 January 2025
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 6
Open AccessRoadmap to advance therapeutics for SYNGAP1-related disorder: a patient organization perspective from SynGAP Research Fund
SYNGAP1-related disorder (SRD) is a developmental and epileptic encephalopathy caused by a disruption of the SYNGAP1 gene. At the beginning of 2024, it is one of many rare monogenic brain disorders without disease-modifying treatments, but that is changing. This article chronicles the last 5 years, beginning when treatments for SRD were not publicly in development, to the start of 2024 when many SRD-specific treatments are advancing. We discuss the progress across many realms that have brought SRD to the forefront of drug development and highlight how Patient Advocacy Groups (PAGs) have had direct roles in accelerating the route to meaningful treatments for our children. We start with a summary of why SRD is an attractive pharmaceutical target. Second, we introduce the disease, the clinical features, and the number of patients. Next, we describe our PAG, our international partners and cite examples of the broad range of activities we believe are accelerating our pace toward treatments. We summarize the current SYNGAP1 pipeline and the status of each public project. Finally, we discuss two open questions that urgently need to be addressed in advance of clinical trials for SRD.
- Open Access
Convergence of autism proteins at the cilium
Hundreds of high confidence autism genes have been identified, yet the relevant etiological mechanisms remain unclear. Gene ontology analyses have repeatedly identified enrichment of proteins with annotated functions in gene expression regulation and neuronal communication. However, proteins are often pleiotropic and these annotations are inherently incomplete. Our recent autism functional genetics work has suggested that these genes may share a common mechanism at the cilium, a membrane-bound organelle critical for neurogenesis, brain patterning, and neuronal activity–all processes strongly implicated in autism. Moreover, autism commonly co-occurs with conditions that are known to involve ciliary-related pathologies, including congenital heart disease, hydrocephalus, and blindness. However, the role of autism genes at the cilium has not been systematically investigated. Here we demonstrate that autism proteins spanning disparate functional annotations converge in expression, localization, and function at cilia, and that patients with pathogenic variants in these genes have cilia-related co-occurring conditions and biomarkers of disrupted ciliary function. This degree of convergence among genes spanning diverse functional annotations strongly suggests that cilia are relevant to autism, as well as to commonly co-occurring conditions, and that this organelle should be explored further for therapeutic potential. One-Sentence Summary Autism genes of diverse functional annotations converge at cilia, deepening our understanding of underlying autism biology and co-occurring conditions.
Open AccessConvergence of autism proteins at the cilium
Hundreds of high confidence autism genes have been identified, yet the relevant etiological mechanisms remain unclear. Gene ontology analyses have repeatedly identified enrichment of proteins with annotated functions in gene expression regulation and neuronal communication. However, proteins are often pleiotropic and these annotations are inherently incomplete. Our recent autism functional genetics work has suggested that these genes may share a common mechanism at the cilium, a membrane-bound organelle critical for neurogenesis, brain patterning, and neuronal activity–all processes strongly implicated in autism. Moreover, autism commonly co-occurs with conditions that are known to involve ciliary-related pathologies, including congenital heart disease, hydrocephalus, and blindness. However, the role of autism genes at the cilium has not been systematically investigated. Here we demonstrate that autism proteins spanning disparate functional annotations converge in expression, localization, and function at cilia, and that patients with pathogenic variants in these genes have cilia-related co-occurring conditions and biomarkers of disrupted ciliary function. This degree of convergence among genes spanning diverse functional annotations strongly suggests that cilia are relevant to autism, as well as to commonly co-occurring conditions, and that this organelle should be explored further for therapeutic potential. One-Sentence Summary Autism genes of diverse functional annotations converge at cilia, deepening our understanding of underlying autism biology and co-occurring conditions.